Sarah Bennett
The JYNNEOS vaccine is a two-dose series, given 28 days apart, that has been approved by the U.S. Food and Drug Administration (FDA) for the prevention of mpox (monkeypox) in people over 18 years old. The vaccine is administered through intradermal injections, which have raised concerns about side effects such as scarring and discoloration. While the vaccine causes a red, raised bump called a wheal, it is not permanent and should not leave a scar. However, individuals with a history of keloid scarring are advised to receive the vaccine subcutaneously to avoid potential scarring.
| Characteristics | Values |
|---|---|
| Does the monkeypox vaccine leave a scar? | The JYNNEOS vaccine does not leave a scar for most people. However, the intradermal method can cause keloid scars (thick, raised scars that can be pink, red, or the same colour or darker than the skin around them) in some people. |
| Who is at risk of scarring? | The CDC advises people under 18 and those with a history of keloid scarring to receive the vaccine via the subcutaneous method. |
| Where is the vaccine administered? | The intradermal method involves an injection into the immune cells between the layers of the skin, often in the forearm. The subcutaneous method involves an injection beneath the skin in the upper arm, upper back, or shoulder. |
| How many doses are required? | The JYNNEOS vaccine is typically given in two doses, at least 28 days apart. |
Explore related products
What You'll Learn
- The JYNNEOS vaccine does not usually leave a scar
- Intradermal injections may cause keloid scars
- The CDC recommends subcutaneous injections for those prone to keloid scarring
- The smallpox vaccine can leave a scar, but it doesn't protect against monkeypox
- The JYNNEOS vaccine is a two-dose series, given 28 days apart
The JYNNEOS vaccine does not usually leave a scar
However, the intradermal injection method has raised concerns about side effects such as scarring and discolouration. The CDC recommends that people with a history of keloid scarring—thick, raised scars—receive the vaccine subcutaneously, beneath the skin in the upper arm or upper back, rather than intradermally. People under 18 should also be given the vaccine subcutaneously. If you have concerns about scarring, you should inform your vaccine provider.
The JYNNEOS vaccine is effective in preventing mpox or lessening the severity of the disease if administered soon after exposure. It is recommended for anyone who may be at current or future risk of getting mpox. The vaccine has shown effectiveness in previous outbreaks of smallpox and mpox, which are viruses in the same family.
The J&J Vaccine: DNA Modifier or Lifesaver?
You may want to see also
Explore related products
Intradermal injections may cause keloid scars
The mpox vaccine causes a red, raised bump called a wheal, which shouldn't leave a scar but can feel itchy. The bump is not permanent and should go away after several weeks. However, intradermal vaccinations may leave a mark that others can see on your forearm. If you have ever had keloid scars (thick, raised scars), you should ask for the vaccine to be given subcutaneously instead.
Keloids are pathological scars that present as nodular lesions that extend beyond the area of injury. They do not spontaneously regress and often continue to grow over time. The abnormal wound-healing process underlying keloid formation results from the lack of control mechanisms that self-regulate cell proliferation and tissue repair. Keloids may lead to cosmetic disfigurement and functional impairment, affecting one's quality of life.
Triamcinolone acetonide intradermal injection is a medicine used to treat thickened scar tissue, including keloid and hypertrophic scars. It is a corticosteroid medicine that occurs naturally in the body and helps reduce inflammation (swelling and redness) associated with active keloid and hypertrophic scars. While it can be effective in treating keloid scars, it may also cause various adverse side effects, such as tiny thread veins (telangiectasia), skin and subcutaneous fat atrophy, pigmentary changes (hypopigmentation and hyperpigmentation), skin necrosis, and ulcerations.
In addition, intradermal corticosteroid injections can be physically challenging due to the density of the lesion, and they are often associated with significant injection pain, requiring local anesthetics. Cushing's syndrome with adrenal insufficiency is another rare but possible complication of intradermal corticosteroid injections, usually reported in children but also observed in a few adult cases. Therefore, it is important to carefully consider the benefits and risks of intradermal injections for keloid scars and consult with a healthcare professional to determine the most appropriate treatment option.
mRNA Vaccines: FDA-Approved or Not?
You may want to see also
Explore related products
The CDC recommends subcutaneous injections for those prone to keloid scarring
The JYNNEOS mpox vaccine is administered in two doses, given 28 days apart. The vaccine is usually delivered intradermally, between the layers of the skin, often on the forearm. However, the intradermal method has raised concerns about potential side effects, such as scarring and discolouration.
The CDC recommends that people who have a history of keloid scarring, which are thick, raised scars that can be pink, red, or darker than the surrounding skin, should opt for subcutaneous injections. Keloid scarring is a potential side effect of the intradermal injection method, and individuals with a history of such scarring can request to receive the vaccine subcutaneously, which means it is injected beneath the skin in the upper arm. This method is also recommended for people under 18 years of age.
The subcutaneous method is equally effective in providing protection against mpox and can be requested by anyone with concerns about keloid scarring. While the intradermal injection may leave a visible mark on the forearm, the subcutaneous injection is administered in areas such as the upper back, just below the shoulder blade, or the shoulder area above the deltoid muscle.
It is important to note that the JYNNEOS vaccine does not typically leave a scar for most people, and the raised bump or wheal at the injection site is not permanent and should go away within a few weeks. However, for those with a history of keloid scarring, the CDC's recommendation of subcutaneous injections provides an alternative method to ensure effective protection without the risk of scarring.
Blue Cross Coverage for Hepatitis A Vaccine
You may want to see also
Explore related products
The smallpox vaccine can leave a scar, but it doesn't protect against monkeypox
The JYNNEOS mpox vaccine is administered via a shallow injection, which causes a wheal—a small, red, raised bump that gradually fades after several weeks. While this bump can feel itchy, it usually does not leave a scar. However, concerns have been raised about the intradermal injection method potentially resulting in keloid scars, particularly for those with a history of such scarring. Keloid scars are thick, raised scars that can be pink, red, or the same colour as the surrounding skin, or darker.
The intradermal method involves delivering the vaccine into the immune cells between the layers of the skin, typically on the forearm. This method allows for a single dose to be split into five, increasing supply. However, there are concerns about potential side effects and questions about its efficacy compared to other methods. As a result, the CDC recommends that individuals under 18 and those with a history of keloid scarring receive the vaccine via the standard regimen, which involves subcutaneous injection. This method delivers the vaccine beneath the skin in the upper arm or the skin of the upper back or shoulder.
It is important to note that the mpox vaccine is different from the smallpox vaccine. While the smallpox vaccine previously left a scar, it does not provide protection against mpox. The mpox vaccine, JYNNEOS, is specifically designed to prevent mpox and smallpox. It contains a weakened vaccinia virus, which is related to the mpox and smallpox viruses but cannot cause disease. The CDC has recommended the use of this vaccine to help control mpox outbreaks.
While the JYNNEOS vaccine is generally safe and effective, it may not be suitable for everyone. Individuals with a history of keloid scarring or preferences should discuss their concerns with their healthcare provider to determine the best vaccination method. Additionally, those who have recovered from mpox may not need the vaccine, as reinfection is rare and typically milder than the initial illness.
Air Travel and Vaccination: What's the Connection?
You may want to see also
Explore related products
The JYNNEOS vaccine is a two-dose series, given 28 days apart
The JYNNEOS vaccine is a two-dose series, with the second dose administered 28 days after the first. This two-dose regimen is recommended to provide stronger protection against mpox, also known as monkeypox. While the first dose offers some protection, the second dose ensures maximum protection.
The JYNNEOS vaccine is approved by the U.S. Food and Drug Administration (FDA) for individuals over 18 years old and has emergency use authorization for those under 18. It is designed to prevent mpox and smallpox, as these viruses are from the same family. The vaccine contains a weakened vaccinia virus, which is related to the mpox and smallpox viruses but cannot cause disease.
The vaccine is typically administered intradermally, between the layers of the skin, often on the forearm. This method allows the vaccine dose to be split into five portions, increasing supply. However, there have been concerns about potential side effects, such as scarring and discoloration, particularly for those with a history of keloid scarring. As a result, the CDC recommends that individuals with a history of keloid scars or those under 18 receive the vaccine subcutaneously, beneath the skin in the upper arm or back.
The mpox vaccine causes a red, raised bump called a wheal, which is a normal reaction that should fade within several weeks and does not typically leave a scar. However, individuals with concerns about scarring can request to receive the vaccine subcutaneously, which is equally effective in preventing mpox.
Whooping Cough Vaccine: A Historical Overview
You may want to see also
Frequently asked questions
The JYNNEOS vaccine does not leave a scar for most people. However, the intradermal method can result in keloid scars (thick, raised scars that can be pink, red, or the same colour or darker than the skin around them).
A keloid scar is a thick, raised scar that can be pink, red, or the same colour or darker than the skin around it.
The CDC advises people under 18 and those with a history of keloid scarring to receive the vaccine via the standard regimen, which is subcutaneous injection.
If you are concerned about keloid scarring, you should inform your vaccine provider and request to receive the vaccine subcutaneously.
